Vicasinabin

Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC50 values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R. Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization[1][2].

Product Specifications

CAS Number

[1433361-02-4]

Product Name Alternative

RG7774

UNSPSC

12352005

Target

Cannabinoid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/vicasinabin.html

Purity

98.37

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CC(C)(C)C1=NC(N2CC[C@@H](C2)O)=C(N=N3)C(N3CC4=NN=NN4C)=N1

Molecular Formula

C15H22N10O

Molecular Weight

358.40

References & Citations

[1]Jean-Michel Adam, et al. Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives. Patent US20130116236A1.|[2]Grether U, et al. RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models. Front Pharmacol. 2024 Jul 12;15:1426446.